Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06914011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

Study acronym: MRD2START
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jan 6, 2026 to May 6, 2026v4 Show 6 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Feb 28, 2031 to Jun 28, 2031
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 8 to 10
    • Study description expanded, about 54 words
    • Study arms: 3 to 2
  2. Start date: Jun 30, 2025 to Jan 6, 2026
    • Publications: details revised at 4 of 4 entries
    v3
  3. Study title shortened, about 7 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06914011
Lead Sponsor Asan Medical Center
Conditions
(from sponsor)		 Esophageal Cancer
Related terms Esophageal Neoplasms
Enrollment 172 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov